focus -WSS

focus

author：fashion 2025-09-30 22:04:27 - browse：76517

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Change Healthcare cyberattack outage could last weeks

focus

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

WuXi out of biotech trade group, U.S. and China relations to blame

Clinical trials giant ICON acquires HumanFirst

Flu vaccine offering decent levels of protection this winter, new data show

Covid isolation guidance eased by the CDC

President Biden's budget: Here's what you might have missed

focus

focus

leisure time

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

First U.S. drug developed to treat liver disease MASH is approved

How one medical school became remarkably diverse

EPA limits use of carcinogenic gas for sterilizing medical devices

Trump demands the U.S. pay no more for drugs than other countries … again

Amid AI frenzy, a top HHS official's quest to create safeguards

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Why getting cancer drugs just got harder for rural patients

Malaria cases in Florida and Texas: Here’s what you need to know

Why scientists need input from humanists on sensitive research

hotspot

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

International team creates first chimeric human

How to address the problem of discarded donor organs

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

A Q&A with Aletha Maybank, AMA’s chief health equity officer

focus

entertainment

leisure time

leisure time